Document text
Principal Investigator: Donald Lo
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2022
Award: $775,431
Funding agency: National Center for Advancing Translational Sciences
TDB scientists have extensive experience in developing novel therapeutic candidates as well as repurposing existing treatments for novel therapeutic purposes. Drug repurposing seeks to explore new uses for existing drugs and therapeutic candidates that already possess detailed pharmacology, formulation, and safety data, which can reduce the time to reach clinical testing for the new indication. In response to the public health crisis, TDB has engaged in several collaborations focused on SARS-CoV-2. Targets under investigation include host defense mechanisms, such as cellular autophagy, viral entry into cells through interaction of the viral spike protein with human cell surface receptors, viral entry cofactors/coreceptors, and viral RNA-dependent RNA polymerase (RdRp). TDB has performed a number of repurposing screening efforts and the IND-directed development of GS-441524. The latter included drug metabolism and pharmacokinetic (PK) studies, human PK modeling, toxicology studies, drug substance manufacture and formulation studies. TDB scientists also have performed AI- assisted virtual compound screens to identify therapeutics for potential COVID-19 treatments. TDB scientists are also contributing assay data and protocols to the Open Data Portal, a resource created by NCATS to house a collection of datasets generated from SARS-CoV-2-related assays against all approved drugs in the NCATS Pharmaceutical Collection (NPC). This effort aims to share COVID-19 related data in an open data-sharing platform to allow research scientists, clinical investigators and public health officials to prioritize promising compounds and repurposed drugs for further development in treating COVID-19. In addition, TDB scientists have participated in the COVID-19 ACTIV TRACE initiative by using the SARS-CoV-2 pseudotyped particle (PP) entry assays to test the efficacies of current therapeutics and vaccinated human sera against the emerging SARS-CoV-2 variants, providing the NIH leadership and scientific community with the important data for surveillance of virus mutations.
List specific collaborations
We have worked in collaboration with experts in and outside of NIH on the development of several assays for repurposing screens of approved drug collections to identify compounds active against SARS-CoV-2 and evaluate efficacies of therapeutics against emerging SARS-CoV-2 variants. The compounds identified from such screens have potential for clinical trials as single agents or in drug combinations to treat COVID-19 patients.
(1) SARS-CoV-2 pseudotyped particle (PP) entry assay. In collaboration with Gary Whittaker (Cornell University), the PPs were generated with three plasmid transfection system containing MLV gag-pol, CoV spike, and luciferase reporter gene w/ viral packaging signal. In the assay process, the PPs deliver luciferase reporter RNA to host cells via spike-mediated cell entry. This assay has been used for screen the inhibitors of SARS-CoV-2 entry as well as the mechanistic study of other compounds identified from other assays. We have used this assay to support the nanobody development against SARS-CoV-2. We also have applied this assay to emerging SARS-CoV-2 spike mutations and have developed about 20 pseudotyped particle (PP) entry assays that containing mutant spike proteins including those from alpha, delta and omicron variants.
(2) Determining the effectiveness of vaccines and therapeutics on SARS-CoV-2 variants. The COVID-19 ACTIV TRACE initiative that is a task under the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership. As the SARS-CoV-2 virus continues to evolve over time, the surveillance of variant mutations, and their impact on COVID-19 vaccines and therapeutics is a critical task that involves multiple government organizations. TDB scientists have employed the SARS-CoV-2 pseudotyped particle entry assay for variants of SARS-CoV-2 spike proteins to test the neutralization potency of SARS-CoV-2 vaccinated sera and therapeutics against more than 20 SARS-CoV-2 variants, including delta and omicron. All the data have been quickly and openly disseminated using the NCATS OpenData Portal, a web-based resource for the research community. Their work has provided the NIH leadership, industry, academic partners, and the external research community with a comprehensive, standardized assessment of how current therapeutics and vaccines are impacted by emerging SARS-CoV-2 variants.
(3) A SARS-CoV-2 cytopathic effect assay in Vero 6 cells in collaboration with the Southern Research Institute (SRI). The compounds and antibodies from NCATYS and outside collaborators were screened using assay ready plates, prepared by NCATS, in the BSL-3 lab at SRI. This assay has also been used to evaluate and confirm anti-SARS-CoV-2 activities of compounds identified from NCATSs BSL-2 assays.
(4) A SARS-CoV-2 3CL protease (also named main protease) assay. This viral protease plays a critical role in SARS-CoV-2 viral replication. We have developed and optimized this enzyme assay and screened a collection of approximately 10,000 compounds. We also applied a virtual modeling screen of 3CLpro with the entire NCATS compound collection and commercial compounds. All the data have been deposited into the OpenData portal for public access.
(5) Homogenous high throughput screening assays for live SARS-CoV-2 virus detection. We have developed two homogeneous assays including the AlphaLISA assay and TR-FRET (HTRF) assay to detect the N-proteins. This type of assays measures the viral proteins that is used as an indicator of SARS-CoV-2 virus replication in cells. It is an alternative live virus assay to the cytopathic effect (CPE) assay of SARS-CoV-2 which uses a surrogate readout (cell death) for host cell infection. We are currently collaborating with the Texas Biomedical Research Institute for compound screening using this assay in their BSL-3 laboratory to identify new antiviral compounds.
(6) Virtual compound screening. Artificial intelligence (AI) assisted virtual compound screening has emerged recently as a new approach to access large compound collections, both internal and commercial ones. The advantages include rapid screening process, reduction of compound screening cost, and accessing large compound collections without physically purchasing and screening most of these compounds. We have developed a new modeling system called biological activity-based modeling (BABM) approach. This new virtual screening method employs compound activity profiles established across multiple assays that have been accumulated in NCATS databased over last 15 years as signatures to predict new hits against new targets. This approach was validated by identifying candidate antivirals for Zika and Ebola viruses based on high-throughput screening data. BABM models were then applied to predict 311 compounds with potential activity against SARS-CoV-2 that has been published in the journal of Nature Biotechnology.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><AI system><Address><Advanced Development><Antibodies><Antiviral Agents><Antiviral Drugs><Antivirals><Artificial Intelligence><Assay><Autophagocytosis><Bioassay><Bioavailability><Biologic Assays><Biologic Availability><Biologic Models><Biologic Products><Biological><Biological Agent><Biological Assay><Biological Availability><Biological Models><Biological Products><Biomedical Research><Biotech><Biotechnology><COVID associated pneumonia><COVID crisis><COVID epidemic><COVID induced pneumonia><COVID infected patient><COVID pandemic><COVID patient><COVID pneumonia><COVID positive patient><COVID related pneumonia><COVID-19><COVID-19 S protein><COVID-19 assay><COVID-19 associated pneumonia><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced pneumonia><COVID-19 infected patient><COVID-19 pandemic><COVID-19 patient><COVID-19 pneumonia><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related pneumonia><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 therapy><COVID-19 treatment><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 assay><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 therapy><COVID19 treatment><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cell Communication and Signaling><Cell Death><Cell Signaling><Cell Surface Receptors><Cells><Clinical><Clinical Evaluation><Clinical Investigator><Clinical Testing><Clinical Trials><CoV-2><CoV2><Collaborations><Collection><Communities><Computer Reasoning><Data><Data Bases><Data Set><Databases><Dataset><Deposit><Deposition><Development><Disease><Disorder><Drug Combinations><Drug Kinetics><Drugs><EBOV><EC 2.7.7.48><Ebola virus><Ebola-like Viruses><Enzyme Gene><Enzymes><Esteroproteases><FRET><Fluorescence Resonance Energy Transfer><Formulation><Förster Resonance Energy Transfer><GS-441524><Genetic Alteration><Genetic Change><Genetic defect><Government><High Throughput Assay><Host Defense Mechanism><Human><Industry><Infection><Intracellular Communication and Signaling><Investigation><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Investigators><Joints><Journals><Laboratories><Leadership><Luciferase Immunologic><Luciferases><Machine Intelligence><Magazine><Measures><Mediating><Medication><Methods><Model System><Modeling><Modern Man><Mutation><NCATS><NIH><Names><National Center for Advancing Translational Sciences><National Institutes of Health><Nature><Neutralization Tests><Non-Polyadenylated RNA><PK/PD><Peptidases><Peptide Hydrolases><Pharmaceutic Preparations><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacokinetics><Pharmacologic Substance><Pharmacological Substance><Pharmacology><Physiologic Availability><Plasmids><Play><Position><Positioning Attribute><Process><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Protocol><Protocols documentation><Public Health><Publishing><RNA><RNA Gene Products><RNA Replicase><RNA-Dependent RNA Polymerase><RNA-Directed RNA Polymerase><Rapid screening><Reporter><Reporter Genes><Research><Research Activity><Research Institute><Research Personnel><Research Resources><Research Support><Researchers><Resources><Ribonucleic Acid><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 assay><SARS-CoV-2 associated pneumonia><SARS-CoV-2 entry inhibitor><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced pneumonia><SARS-CoV-2 infected patient><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 pneumonia><SARS-CoV-2 positive patient><SARS-CoV-2 related pneumonia><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 entry inhibitor><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Societies><Standardization><System><Testing><Texas><Therapeutic><Therapeutic Intervention><Time><Toxicology><Transfection><Translational Research><Translational Science><Treatment Efficacy><United States National Institutes of Health><Universities><Vaccinated><Vaccines><Variant><Variation><Viral><Viral Gene Products><Viral Gene Proteins><Viral Packaging><Viral Proteins><Virus><Virus Packagings><Virus Replication><Work><Wuhan coronavirus><ZIKV><Zika Virus><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antibody neutralization test><antiviral compound><antiviral medication><antiviral therapeutic><assess effectiveness><atypical pneumonia><autophagy><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><biologic><biological signal transduction><biologics><biopharmaceutical><biotherapeutic agent><block SARS-CoV-2 entry><block severe acute respiratory syndrome coronavirus 2 entry><clinical candidate><clinical development><clinical efficacy><clinical investigation><clinical test><cofactor><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 assay><coronavirus disease 2019 associated pneumonia><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced pneumonia><coronavirus disease 2019 infected patient><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 pneumonia><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related pneumonia><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease associated pneumonia><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced pneumonia><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease pneumonia><coronavirus disease positive patient><coronavirus disease related pneumonia><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 pneumonia><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><cost><data base><data portal><data sharing portal><determine effectiveness><developmental><drug candidate><drug development><drug metabolism><drug repurposing><drug/agent><ebolavirus><effectiveness assessment><effectiveness evaluation><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><evaluate effectiveness><evaluate efficacy><examine efficacy><experience><genome mutation><hCoV19><high throughput screening><inhibit SARS-CoV-2 entry><inhibit severe acute respiratory syndrome coronavirus 2 entry><internet resource><intervention efficacy><intervention therapy><model development><mutant><nCoV2><nanobodies><nanobody><necrocytosis><new approaches><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel approaches><novel drug treatments><novel drugs><novel strategies><novel strategy><novel therapeutics><novel therapy><on-line compendium><on-line resource><online compendium><online resource><open data><open science><open-source data><operation><pandemic><pandemic disease><particle><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pharmacokinetic model><pharmacokinetics and pharmacodynamics><pneumonia due to COVID><pneumonia due to COVID-19><pneumonia due to SARS-CoV-2><pneumonia due to coronavirus disease><pneumonia due to coronavirus disease 2019><pneumonia due to severe acute respiratory syndrome coronavirus 2><pneumonia in COVID><pneumonia in COVID-19><pneumonia in SARS-CoV-2><pneumonia in coronavirus disease><pneumonia in coronavirus disease 2019><pneumonia in severe acute respiratory syndrome coronavirus 2><public-private partnership><repurposing agent><repurposing medication><research clinical testing><response><screening><sdAb><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 associated pneumonia><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced pneumonia><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 pneumonia><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related pneumonia><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><sharing platform><single domain antibodies><small molecule><social role><surveillance data><therapeutic agent development><therapeutic candidate><therapeutic development><therapeutic efficacy><therapeutic vaccine><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><therapy efficacy><translation research><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment vaccines><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine effectiveness><vaccine for novel coronavirus><vaccine for the treatment><vaccine for treatment><viral RNA><viral detection><viral multiplication><viral replication><virtual><virtual model><virtual screening><virtual screenings><virus RNA><virus detection><virus multiplication><virus protein><web resource><web-based resource><zikav><β CoV><β coronavirus><βCoV>